Davis, California, USA
May 29, 2015

Marrone Bio Innovations, Inc. (the "Company") (NASDAQ:MBII) today announced that it has received a letter from The NASDAQ Stock Market LLC ("NASDAQ") indicating that a NASDAQ Hearings Panel (the "Panel") granted the Company's request to extend the stay of any suspension in trading in the Company's common stock on NASDAQ at least pending the completion of the Company's scheduled hearing before the Panel and a final determination regarding the Company's listing status. As previously announced, as part of the Company's request for a hearing before the Panel, the Company requested the extended stay of any suspension in trading. Also as previously announced, the hearing is scheduled for June 18, 2015. Although the Panel typically issues decisions within 30 days of the hearing date, there is no requirement that the Panel do so within that time frame.

At the hearing, the Company plans to present a definitive plan to regain compliance with the NASDAQ listing rule that requires the Company to be current in the filing of its periodic financial reports with the Securities and Exchange Commission and to request an extension of time to file its delayed reports. The Panel has the discretion to grant the Company an extension to do so through November 2, 2015. 

Website: http://marronebioinnovations.com/

Published: May 29, 2015